Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir Alafenamide

Sofía Scévola; Arkaitz Imaz; Mackenzie L Cottrell; Jordi Niubo; Brian Van Horne; Juan Tiraboschi; Maria Saumoy; Sandra Morenilla; Irene Soriano; Angela D M Kashuba; Daniel Podzamczer

doi:10.1093/cid/ciac410

Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir Alafenamide

Clin Infect Dis. 2022 Nov 30;75(11):2012-2015. doi: 10.1093/cid/ciac410.

Affiliations

¹ HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
² Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
³ Department of Microbiology, Bellvitge University Hospital, Bellvitge Biomedical Research Institute, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.

PMID: 35616112
DOI: 10.1093/cid/ciac410

Abstract

Doravirine (DOR) concentrations and HIV-1 RNA were evaluated in genital fluids from adults with HIV on stable therapy who switched to DOR + FTC/TAF. High protein-unbound DOR concentrations were observed in both seminal plasma and cervicovaginal fluid. DOR + FTC/TAF maintained viral suppression in genital fluids in all but 1 participant.

Keywords: HIV-1; antiretroviral therapy; cervicovaginal fluid; doravirine; semen.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-HIV Agents* / therapeutic use
Emtricitabine / therapeutic use
Genitalia
HIV Infections* / drug therapy
HIV-1* / genetics
Humans
RNA / therapeutic use

Substances

tenofovir alafenamide
doravirine
Anti-HIV Agents
emtricitabine tenofovir alafenamide
Emtricitabine
RNA